bioRxiv Science⌕ Search

Biology subjects

Latawa, P.

Publications and source records attributed to Latawa, P..

2 recordsLinked to original sources

AptaBERT: Predicting aptamer binding interactions

AO_SCPLOWBSTRACTC_SCPLOWAptamers, short single-stranded DNA or RNA, are promising as future diagnostic and therapeutic agents. Traditional selection methods, such as the Systemic Evolution of Ligands by Exponential Enrichment (SELEX), are not without limitations being both resource-intensive and prone to biases in library construction and the selection phase. Leveraging Dianoxs extensive aptamer database, we introduce a novel computational approach, AptaBERT, built upon the BERT architecture. This method utilizes self-supervised pre-training on vast amounts of data, followed by supervised fine-tuning to enhance the prediction of aptamer interactions with proteins and small molecules. AptaBERT is fine-tuned for binary classification tasks, distinguishing between positive and negative interactions with proteins and small molecules. AptaBERT achieves a ROC-AUC of 96% for protein interactions, surpassing existing models by at least 15%. For small molecule interactions, AptaBERT attains an ROC-AUC of 85%. Our findings demonstrate AptaBERTs superior predictive capability and its potential to identify novel aptamers binding to targets.

bioinformatics↗

A Computational Modeling Framework to Analyze Synovial-Tissue Based Drug Targets and Diagnostic Biomarkers in Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is an inflammatory autoimmune disease that affects 23 million people worldwide. It is a clinically heterogeneous disorder characterized by the attack of inflammatory chemicals on the synovial tissue that lines joints. It is advantageous to develop effective, targeted treatments and identify specific diagnostic biomarkers for RA before extensive joint degradation, bone erosion, and cartilage destruction. Current modes of RA treatments have alleviated and notably halted the progression of RA. Despite this, not many patients reach low disease activity status after treatment, and a significant number of patients fail to respond to medication due to drug non-specificity. While the reasons for these rates remain unknown, the cellular and molecular signatures present in the synovial tissue for RA patients likely play a role in the varied treatment response. Thus, a drug that particularly targets specific genes and networks may have a significant effect in halting the progression of RA. This study evaluates and proposes potential drug targets through in silico mathematical modeling of various pathways of interest in RA. To understand how drugs interact with genes, we built a mathematical model with 30 two-gene and three-gene network interactions and analyzed the effect of 92 different perturbations to rate constants. We determined that inhibition of the LCK-CD4, VAV1-CD4, and MLT-ROR pathways could potentially serve as drug targets. We also found that increased activity of the DEC2-IL1{beta} and the NF-kB-interleukin pathway and the decreased activity of the TNF--REV-ERB pathway could serve as diagnostic biomarkers.

systems biology↗